Bioreactors get personal

Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individuali...

Descripción completa

Detalles Bibliográficos
Autores principales: Somerville, Robert P.T., Dudley, Mark E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518529/
https://www.ncbi.nlm.nih.gov/pubmed/23243620
http://dx.doi.org/10.4161/onci.21206
_version_ 1782252570115309568
author Somerville, Robert P.T.
Dudley, Mark E.
author_facet Somerville, Robert P.T.
Dudley, Mark E.
author_sort Somerville, Robert P.T.
collection PubMed
description Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individualized cell therapies. Such bioreactors might increase the number of patients that get access to this promising therapeutic modality.
format Online
Article
Text
id pubmed-3518529
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185292012-12-14 Bioreactors get personal Somerville, Robert P.T. Dudley, Mark E. Oncoimmunology Author's View Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individualized cell therapies. Such bioreactors might increase the number of patients that get access to this promising therapeutic modality. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518529/ /pubmed/23243620 http://dx.doi.org/10.4161/onci.21206 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Somerville, Robert P.T.
Dudley, Mark E.
Bioreactors get personal
title Bioreactors get personal
title_full Bioreactors get personal
title_fullStr Bioreactors get personal
title_full_unstemmed Bioreactors get personal
title_short Bioreactors get personal
title_sort bioreactors get personal
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518529/
https://www.ncbi.nlm.nih.gov/pubmed/23243620
http://dx.doi.org/10.4161/onci.21206
work_keys_str_mv AT somervillerobertpt bioreactorsgetpersonal
AT dudleymarke bioreactorsgetpersonal

Ejemplares similares